Expression of p63 protein in pulmonary adenocarcinomas as factor of poor prognosis

Abstract

Aim. To study the spectrum of cellular molecular-biological markers and identify those of them that can be used as prognostic factors for the clinical course of pulmonary adenocarcinoma.

Material and Methods. In the given work archive material of 129 patients with confirmed diagnosis of pulmonary adenocarcinoma was used. In the work, histological, immunohistochemical, molecular-genetic and statistical methods were used.

Results. In 29 cases (47.5%) of pulmonary adenocarcinoma, focal cytoplasmic and/or nuclear expression of p63 protein was observed in different proportions of cells. With expression of p63 in tumor cells, relapse-free survival was on average 25.7±5.1 months, while in patients with no expression of р63 it was 26.1±2.8 months. This parameter did not influence the overall survival of patients which was on average 33.6±2.7 months.

Conclusion. A weak tendency to reduction of relapse-free survival of patients with p63-positive pulmonary carcinoma of lungs was revealed. Identification of p63 in pulmonary adenocarcinoma may be regarded as a factor of unfavorable prognosis and of risk of faster tumor progression, which requires further study to increase the statistical value of research.

Keywords

expression / p63 / pulmonary adenocarcinoma / pulmonary cancer / TP63 gene

References

[1] Travis WD, Brambilla E, Burke AP, et al. editors. WHO Classification of tumours of the lung, pleura, thymus and heart. 4th ed. Lyon: IARC; 2015.

[2] Travis W.D., Brambilla E., Burke A.P., et al., editors. WHO Classification of tumours of the lung, pleura, thymus and heart. 4th ed. Lyon: IARC; 2015.

[3] Travis WD, Brambilla E, Burke AP, et al. editors. WHO Classification of tumours of the lung, pleura, thymus and heart. 4th ed. Lyon: IARC; 2015.

[4] Mountzios G, Dimopoulos MA, Soria JC, et al. Histopathologic and genetic alterations as predictors of response to treatment and survival in lung cancer: a review of published data. Critical Reviews Oncology/Hematology. 2010;75(2):94-109. doi:10. 1016/j.critrevonc.2009.10.002

[5] Mountzios G., Dimopoulos M.A., Soria J.C., et al. Histopathologic and genetic alterations as predictors of response to treatment and survival in lung cancer: a review of published data // Critical Reviews Oncology/Hematology. 2010. Vol. 75, №2. P. 94-109. doi:10.1016/j.critrevonc.2009.10.002

[6] Mountzios G, Dimopoulos MA, Soria JC, et al. Histopathologic and genetic alterations as predictors of response to treatment and survival in lung cancer: a review of published data. Critical Reviews Oncology/Hematology. 2010;75(2):94-109. doi:10. 1016/j.critrevonc.2009.10.002

[7] Langer CJ, Besse B, Gualberto A, et al. The evolving role of histology in the management of advanced non-small-cell lung cancer. Journal of Clinical Oncology. 2010;28(36):5311-20. doi:10.1200/JCO.2010. 28.8126

[8] Langer C.J., Besse B., Gualberto A., et al. The evolving role of histology in the management of advanced non-small-cell lung cancer // Journal of Clinical Oncology. 2010. Vol. 28, №36. P. 5311-5320. doi:10.1200/JCO.2010.28.8126

[9] Langer CJ, Besse B, Gualberto A, et al. The evolving role of histology in the management of advanced non-small-cell lung cancer. Journal of Clinical Oncology. 2010;28(36):5311-20. doi:10.1200/JCO.2010. 28.8126

[10] Sinna EA, Ezzat N, Sherif GM. Role of thyroid transcription factor-1 and P63 immunocytochemistry in cytologic typing of non-small cell lung carcinomas. Journal of the Egyptian National Cancer Institute. 2013;25(4):209-18. doi:10.1016/j.jnci.2013.05.005

[11] Sinna E.A., Ezzat N., Sherif G.M. Role of thyroid transcription factor-1 and P63 immunocytochemistry in cytologic typing of non-small cell lung carcinomas // Journal of the Egyptian National Cancer Institute. 2013. Vol. 25, №4. P. 209-218. doi:10.1016/j.jnci. 2013.05.005

[12] Sinna EA, Ezzat N, Sherif GM. Role of thyroid transcription factor-1 and P63 immunocytochemistry in cytologic typing of non-small cell lung carcinomas. Journal of the Egyptian National Cancer Institute. 2013;25(4):209-18. doi:10.1016/j.jnci.2013.05.005

[13] Koh J, Go H, Kim MY, et al. A comprehensive immunohistochemistry algorithm for the histological sub typing of small biopsies obtained from non-small cell lung cancers. Histopathology. 2014; 65(6):868-78. doi:10.1111/his.12507

[14] Koh J., Go H., Kim M.Y., et al. A comprehensive immunohistochemistry algorithm for the histological subtyping of small biopsies obtained from non-small cell lung cancers // Histopathology. 2014. Vol. 65, №6. P. 868-878. doi:10.1111/his.12507

[15] Koh J, Go H, Kim MY, et al. A comprehensive immunohistochemistry algorithm for the histological sub typing of small biopsies obtained from non-small cell lung cancers. Histopathology. 2014; 65(6):868-78. doi:10.1111/his.12507

[16] Pelosi G, Rossi G, Bianchi F, et al. Immunohistochemistry by means of widely agreed-upon markers (cytokeratins 5/6 and 7, p63, thyroid transcription factor-1, and vimentin) on small biopsies of non-small cell lung cancer effectively parallels the corresponding profiling and eventual diagnoses on surgical specimens. Journal Thoracic Oncology. 2011;6(6):1039-49. doi:10.1097/JTO.0b013e3182 11dd16

[17] Pelosi G., Rossi G., Bianchi F., et al. Immunohistochemistry by means of widely agreed-upon markers (cytokeratins 5/6 and 7, p63, thyroid transcription factor-1, and vimentin) on small biopsies of non-small cell lung cancer effectively parallels the corresponding profiling and eventual diagnoses on surgical specimens // Journal Thoracic Oncology. 2011. Vol. 6, №6. P. 1039-1049. doi:10.1097/JTO. 0b013e318211dd16

[18] Pelosi G, Rossi G, Bianchi F, et al. Immunohistochemistry by means of widely agreed-upon markers (cytokeratins 5/6 and 7, p63, thyroid transcription factor-1, and vimentin) on small biopsies of non-small cell lung cancer effectively parallels the corresponding profiling and eventual diagnoses on surgical specimens. Journal Thoracic Oncology. 2011;6(6):1039-49. doi:10.1097/JTO.0b013e3182 11dd16

[19] Terry J, Leung S, Laskin J, et al. Optimal immu-nohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. American Journal of Surgery Pathology. 2010; 34(12):1805-11. doi:10.1097/ PAS.0b013e3181f7dae3

[20] Terry J., Leung S., Laskin J., et al. Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples // American Journal of Surgery Pathology. 2010. Vol. 34, №12. P. 1805-1811. doi:10.1097/PAS.0b013e3181f7dae3

[21] Terry J, Leung S, Laskin J, et al. Optimal immu-nohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. American Journal of Surgery Pathology. 2010; 34(12):1805-11. doi:10.1097/ PAS.0b013e3181f7dae3

[22] Kargi A, Gurel D, Tuna B. The diagnostic value of TTF-1, CK 5/6, and p63 immunostaining in classification of lung carcinomas. Applied Immunohistochemistry & Molecular Morphology. 2007;15(4): 415-20. doi:10.1097/PAI.0b013e31802fab75

[23] Kargi A., Gurel D., Tuna B. The diagnostic value of TTF-1, CK 5/6, and p63 immunostaining in classification of lung carcinomas // Applied Immunohistochemistry & Molecular Morphology. 2007. Vol. 15, №4. P. 415-420. doi:10.1097/PAI.0b013e31802fab75

[24] Kargi A, Gurel D, Tuna B. The diagnostic value of TTF-1, CK 5/6, and p63 immunostaining in classification of lung carcinomas. Applied Immunohistochemistry & Molecular Morphology. 2007;15(4): 415-20. doi:10.1097/PAI.0b013e31802fab75

[25] Nicholson AG, Gonzalez D, Shah P, et al. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. Journal Thoracic Oncology. 2010;5(4):436-41. doi:10.1097/ JTO.0b013e3181c6ed9b

[26] Nicholson A.G., Gonzalez D., Shah P., et al. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis // Journal Thoracic Oncology. 2010. Vol. 5, №4. P. 436-441. doi:10.1097/JTO.0b013e3181c6ed9b

[27] Nicholson AG, Gonzalez D, Shah P, et al. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. Journal Thoracic Oncology. 2010;5(4):436-41. doi:10.1097/ JTO.0b013e3181c6ed9b

[28] Warth A, Muley T, Herpel E, et al. Large-scale comparative analyses of immunomarkers for diagnostic sub typing of non-small-cell lung cancer biopsies. Histopathology. 2012;61(6):1017-25. doi:10.1111/ j.1365-2559.2012.04308.x

[29] Warth A., Muley T., Herpel E., et al. Large-scale comparative analyses of immunomarkers for diagnostic subtyping of non-small-cell lung cancer biopsies // Histopathology. 2012. Vol. 61, №6. P. 1017-1025. doi:10.1111/j.1365-2559.2012.04308.x

[30] Warth A, Muley T, Herpel E, et al. Large-scale comparative analyses of immunomarkers for diagnostic sub typing of non-small-cell lung cancer biopsies. Histopathology. 2012;61(6):1017-25. doi:10.1111/ j.1365-2559.2012.04308.x

[31] Nobre AR, Albergaria A, Schmitt F. p40: a p63 isoform useful for lung cancer diagnosis – a review of the physiological and pathological role of p63. Acta Cytologica. 2013;57(1):1-8. doi:10.1159/000345245

[32] Nobre A.R., Albergaria A., Schmitt F. p40: a p63 isoform useful for lung cancer diagnosis – a review of the physiological and pathological role of p63 // Acta Cytologica. 2013. Vol. 57, №1. P. 1-8. doi:10.1159/000345245

[33] Nobre AR, Albergaria A, Schmitt F. p40: a p63 isoform useful for lung cancer diagnosis – a review of the physiological and pathological role of p63. Acta Cytologica. 2013;57(1):1-8. doi:10.1159/000345245

[34] Bir F, Aksoy AA, Satiroglu-Tufan NL, et al. Potential utility of p63 expression in differential diagnosis of non-small-cell lung carcinoma and its effect on prognosis of the disease. Medical Science Monitor. 2014;9(20):219-26. doi:10.12659/MSM.890394

[35] Bir F., Aksoy A. A., Satiroglu-Tufan N.L., et al. Potential utility of p63 expression in differential diagnosis of non-small-cell lung carcinoma and its effect on prognosis of the disease // Medical Science Monitor. 2014. Vol. 9, №20. P. 219-226. doi:10.12659/MSM.890394

[36] Bir F, Aksoy AA, Satiroglu-Tufan NL, et al. Potential utility of p63 expression in differential diagnosis of non-small-cell lung carcinoma and its effect on prognosis of the disease. Medical Science Monitor. 2014;9(20):219-26. doi:10.12659/MSM.890394

[37] Brierley JD, Gospodarowicz MK, Wittekind Chr. TNM Classification of Malignant Tumours. 8th ed. Wiley-Blackwell; 2016.

[38] Brierley J.D., Gospodarowicz M.K., Wittekind Chr. TNM Classification of Malignant Tumours. 8th ed. Wiley-Blackwell; 2016.

[39] Brierley JD, Gospodarowicz MK, Wittekind Chr. TNM Classification of Malignant Tumours. 8th ed. Wiley-Blackwell; 2016.

[40] Zaridze DG. Carcinogenesis. Moscow; 2004. (In Russ).

[41] Заридзе Д.Г., ред. Канцерогенез. М.; 2004.

[42] Zaridze DG. Carcinogenesis. Moscow; 2004. (In Russ).

[43] Gonfloni S, Caputo V, Iannizzotto V. P63 in health and cancer. International Journal Developmental Biology. 2015;59(1-3):87-93. doi:10.1387/ijdb.150045sg

[44] Gonfloni S., Caputo V., Iannizzotto V. P63 in health and cancer // International Journal Developmental Biology. 2015. Vol. 59, №1-3. P. 87-93. doi:10.1387/ijdb.150045sg

[45] Gonfloni S, Caputo V, Iannizzotto V. P63 in health and cancer. International Journal Developmental Biology. 2015;59(1-3):87-93. doi:10.1387/ijdb.150045sg

[46] Adorno M, Cordenonsi M, Montagner M, et al. A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis // Cell. 2009; 137(1):87-98. doi:10.1016/j.cell.2009.01.039

[47] Adorno M., Cordenonsi M., Montagner M., et al. A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis // Cell. 2009. Vol. 137, №1. P. 87-98. doi:10.1016/j.cell.2009.01.039

[48] Adorno M, Cordenonsi M, Montagner M, et al. A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis // Cell. 2009; 137(1):87-98. doi:10.1016/j.cell.2009.01.039

[49] Pelosi G, Pasini F, Olsen SC, et al. p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas? Journal of Pathology. 2002;198(1):100-9.

[50] Pelosi G., Pasini F., Olsen S. C., et al. p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas? // Journal of Pathology. 2002. Vol. 198, №1. P. 100-109.

[51] Pelosi G, Pasini F, Olsen SC, et al. p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas? Journal of Pathology. 2002;198(1):100-9.

[52] Massion PP, Taflan PM, Jamshedur RSM, et al. Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Research. 2003;63(21):7113-21.

[53] Massion P.P., Taflan P.M., Jamshedur R.S.M., et al. Significance of p63 amplification and overexpression in lung cancer development and prognosis // Cancer Research. 2003. Vol. 63, №21. P. 7113-7121.

[54] Massion PP, Taflan PM, Jamshedur RSM, et al. Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Research. 2003;63(21):7113-21.

[55] Wang BY, Gil J, Kaufman D, et al. P63 in pulmonary epithelium, pulmonary squamous neoplasms, and other pulmonary tumors. Human Pathology. 2002;33(9):921-6 doi:10.1053/hupa.2002.126878

[56] Wang B.Y., Gil J., Kaufman D., Gan L., et al. P63 in pulmonary epithelium, pulmonary squamous neoplasms, and other pulmonary tumors // Human Pathology. 2002. Vol. 33, №9. P. 921-926. doi:10.1053/hupa.2002.126878

[57] Wang BY, Gil J, Kaufman D, et al. P63 in pulmonary epithelium, pulmonary squamous neoplasms, and other pulmonary tumors. Human Pathology. 2002;33(9):921-6 doi:10.1053/hupa.2002.126878

[58] Iacono M, Monica V, Saviozzi S, et al. p63 and p73 Isoform Expression in Non-small Cell Lung Cancer and Corresponding Morphological Normal Lung Tissue. Journal of Thoracic Oncology. 2011;6(3): 473-81. doi:10.1097/JTO.0b013e31820b86b0

[59] Iacono M., Monica V., Saviozzi S., et al. p63 and p73 Isoform Expression in Non-small Cell Lung Cancer and Corresponding Morphological Normal Lung Tissue // Journal of Thoracic Oncology. 2011. Vol. 6, №3. P. 473-481. doi:10.1097/JTO.0b013 e31820b86b0

[60] Iacono M, Monica V, Saviozzi S, et al. p63 and p73 Isoform Expression in Non-small Cell Lung Cancer and Corresponding Morphological Normal Lung Tissue. Journal of Thoracic Oncology. 2011;6(3): 473-81. doi:10.1097/JTO.0b013e31820b86b0

[61] Narahashi T, Niki T, Wang T, et al. Cytoplasmic localization of p63 is associated with poor patient survival in lung adenocarcinoma. Histopathology. 2006;49(4):349-57. doi:10.1111/j.1365-2559.2006. 02507.x

[62] Narahashi T., Niki T., Wang T., et al. Cytoplasmic localization of p63 is associated with poor patient survival in lung adenocarcinoma // Histopathology. 2006. Vol. 49, №4. P. 349-357. doi:10.1111/j.1365-2559.2006.02507.x

[63] Narahashi T, Niki T, Wang T, et al. Cytoplasmic localization of p63 is associated with poor patient survival in lung adenocarcinoma. Histopathology. 2006;49(4):349-57. doi:10.1111/j.1365-2559.2006. 02507.x

[64] Ko E, Lee BB, Kim Y, et al. Association of RASSF1A and p63 with poor recurrence-free survival in node-negative stage I-II non-small cell lung cancer. Clinical Cancer Research. 2013;19(5): 1204-12. doi:10.1158/1078-0432.CCR-12-2848

[65] Ko E., Lee B.B., Kim Y., et al. Association of RASS F1A and p63 with poor recurrence-free survival in node-negative stage I-II non-small cell lung cancer // Clinical Cancer Research. 2013. Vol. 19, №5. P 1204-1212. doi:10.1158/1078-0432.CCR-12-2848

[66] Ko E, Lee BB, Kim Y, et al. Association of RASSF1A and p63 with poor recurrence-free survival in node-negative stage I-II non-small cell lung cancer. Clinical Cancer Research. 2013;19(5): 1204-12. doi:10.1158/1078-0432.CCR-12-2848

[67] Aubry MC, Roden A, Murphy SJ, et al. Chromosomal rearrangements and copy number abnormalities of TP63 correlate with p63 protein expression in lung adenocarcinoma. Modern Pathology. 2015; 28(3):359-66. doi:10.1038/modpathol.2014.118

[68] Aubry M.C., Roden A., Murphy S.J., et al. Chromosomal rearrangements and copy number abnormalities of TP63 correlate with p63 protein expression in lung adenocarcinoma // Modern Pathology. 2015. Vol. 28, №3. P. 359-366. doi:10.1038/modpathol. 2014.118

[69] Aubry MC, Roden A, Murphy SJ, et al. Chromosomal rearrangements and copy number abnormalities of TP63 correlate with p63 protein expression in lung adenocarcinoma. Modern Pathology. 2015; 28(3):359-66. doi:10.1038/modpathol.2014.118

RIGHTS & PERMISSIONS

Byakhova M.M., Glazkov A.A., Vinogradov I.Y., Frank G.A.